Equfina Special Precautions

IMPORTANT PRECAUTIONS: 1. This drug may induce daytime somnolence or sudden onset of sleep with no signs. Therefore, patients should be cautioned against engaging in dangerous activities such as driving a car, operating machinery, or working at heights under administration of this drug [see ADVERSE REACTIONS].
2. Equfina may induce impulse-control disorder such as pathological gambling (persistent repetition of gambling despite socially adverse consequences including disruption of personal life), pathological hypersexuality, compulsive shopping, and hyperphagia. Therefore, if any of such symptoms is observed, appropriate measures including discontinuation of treatment should be taken. In addition, patients and their family members should be informed of these symptoms of impulse-control disorder [see ADVERSE REACTIONS].
3. Equfina may induce orthostatic hypotension or hypotension. Therefore, if dizziness, lightheadedness, wobble, or any other symptoms which are suspected orthostatic hypotension or hypotension are observed, appropriate measures including discontinuation of treatment should be taken. Patients with Parkinson's disease are at an increased risk of falls associated with motor dysfunction and, if orthostatic hypotension occurs, they may experience fracture and/or trauma due to a fall [see ADVERSE REACTIONS].
PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS: Patients with complications or history of diseases: Patients with active or a history of retina-related disease: Patients with retinal degeneration, uveitis, hereditary retinopathy, or severe progressive diabetic retinopathy, patients with a history of eye disorders that are highly likely to affect the retina (eg, retinitis pigmentosa, any form of active retinopathy, family history of hereditary retinal disease), and patients with albinism should be regularly monitored for any change in acuity- and field-related symptoms. Such patients were excluded from clinical studies. In animals, a repeated-dose oral toxicity study (rats) and carcinogenicity studies (mice and rats) demonstrated dose- and duration-dependent retinal degeneration and exacerbation due to light exposure in rats. This change was not observed in monkeys.
Patients with hepatic impairment: Patients with severe hepatic impairment (Child-Pugh C): Equfina should not be administered. Blood concentration of this drug may increase. Such patients were excluded from clinical studies [see CONTRAINDICATIONS].
Patients with moderate hepatic impairment (Child-Pugh B): Blood concentration of this drug may increase [see PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION under Dosage & Administration and Pharmacology: PHARMACOKINETICS under Actions].
Patients with reproductive potential: Women of childbearing potential should be instructed to use appropriate contraception during treatment with this drug and for a certain period of time after completion of treatment with this drug. In animals (rats), a reproductive and developmental toxicity study showed mild decreases in the corpora lutea count and the number of implantation sites in female rats.
Patients with congenital short QT syndrome: Equfina should not be used in patients with congenital short QT syndrome [see Pharmacology: Pharmacodynamics: CLINICAL STUDIES under Actions].
Use in Pregnancy: Equfina should not be used in pregnant women or women who may possibly be pregnant [see CONTRAINDICATIONS].
In animal studies, administration of this drug during an organogenesis period in pregnant rats induced ectopic testis, urologic changes (ureteric dilatation and renal pelvis dilatation), and skeletal abnormality in fetuses. In addition, coadministration with levodopa/carbidopa resulted in an increase in the incidence of skeletal malformation (bowing of scapula and shortening/bowing/thickening of long bones). In rabbits, coadministration with levodopa/carbidopa resulted in an increase in the incidence of cardiovascular malformation (ventricular septal defect and dilation of 1 blood vessel leading directly to the heart), which was observed with levodopa/carbidopa alone, as well as an increase in the rate of embryonic or fetal death. A study in which rat dams were administered this drug pre- and post-natally showed an increased mortality and changes associated with hepatobiliary disorder (yellow/orange discoloration of the skin and skull bone) in offspring.
Use in Lactation: Breastfeeding should be discontinued during treatment with this drug.
In animals (rats), administration of safinamide to lactating dams was associated with vacuoles in the hepatocyte and reduced glycogen in suckling offspring. In addition, safinamide was detected in the plasma of suckling offspring, suggesting excretion of safinamide in milk.
Use in Children: There was no clinical study conducted in children.